Bio Protocol (@bioprotocol): Today, bringing a single drug to market costs about $1 billion, a figure that surprises even experienced industry experts.

Today, bringing a single drug to market costs about $1 billion, a figure that surprises even experienced industry experts. In contrast, adjusted for inflation, one billion dollars in the 1950s could have launched dozens of drugs, revolutionizing treatment options and saving countless lives. This change in capital efficiency is not only due to modern science becoming more complex or the inherent risks in drug development. It reflects deeper issues in how legacy institutions have managed the drug discovery process. Over decades, layers of regulation, bureaucracy, and risk-aversion have stifled innovation and slowed the arrival of groundbreaking therapies to patients. The current biotech landscape is a paradox. On one hand, we benefit from remarkable advances such as genome editing, high-throughput screening, and AI-driven diagnostics. On the other hand, the infrastructure supporting drug development has grown cumbersome, preventing nimble startups and established companies from using these innovations effectively. The result is a system that uses vast amounts of capital for each new therapy, leaving fewer resources for diverse research and broader disease treatment. This inefficiency significantly impacts global healthcare. In an ideal world, a single billion-dollar investment would produce a portfolio of drugs addressing both common and rare diseases. Instead, we see expensive therapies that often serve only a small segment of patients. This leads to higher drug prices, limited access to essential medications, and a slower pace of medical progress. It is time to rethink the process. Modernizing the drug development paradigm is not just about reducing costs; it is about reimagining how we harness science for the common good. One promising solution is decentralizing the research and development ecosystem. Decentralized science initiatives offer new models that leverage networks of researchers, investors, and patients. Free from the constraints of legacy institutions, these initiatives can create a more agile, transparent, and efficient framework for drug discovery. Embracing this shift means channeling billions into a diverse range of research projects rather than into bureaucratic overhead. It means empowering innovators to take calculated risks, collaborate across disciplines, and use advanced technology without being held back by outdated systems. The future can be defined not by exorbitant costs and limited options, but by a dynamic ecosystem that prioritizes patient outcomes and scientific breakthroughs.